Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis

Medical expulsive therapy (MET) represents an effective adjunctive treatment for nonpregnant patients with symptomatic urolithiasis. Tamsulosin is classified by the FDA as a category B medication; however no published data exists for human pregnancy.

Our objective was to explore the safety and efficacy of tamsulosin therapy for symptomatic urolithiasis occurring during pregnancy

We retrospectively identified patients treated with tamsulosin for stone disease during pregnancy at the Mayo Clinic during the 2000-2014 interval This MET cohort was matched 2:1 to pregnant women with symptomatic urolithiasis during pregnancy who did not receive MET Groups were compared using linear mixed models for continuous variables and exact conditional logistic regression models for nominal variables, in order to take into account correlation due to matching

A total of 27 patients receiving MET comprised the study cohort Median duration of antepartum tamsulosin exposure was 3 days (range 1-110), occurring during the first, second and third trimester in 3 (11%), 11 (40 7%), and 18 (67%) patients respectively Mean gestational age at delivery was 38 1 weeks (SD 2 4); 6 (22%) infants were born preterm All infant birthweights were considered appropriate for gestational age, and no cases of spontaneous abortion, intrauterine demise, or neonatal congenital anomalies were encountered Comparison between the MET and control groups demonstrated no significant differences in maternal or infant outcomes for any of the examined variables

Tamsulosin MET does not appear to be associated with adverse maternal or fetal outcomes, and may be considered as adjunctive therapy for urolithiasis during pregnancy

The Journal of urology 2015 Jul 02 [Epub ahead of print]

George Bailey, Lisa Vaughan, Carl Rose, Amy Krambeck

Department of Urology, Mayo Clinic, Rochester, Minnesota , Health Sciences Research, Mayo Clinic, Rochester Minnesota , Department of Obstetrics and Gynecology, Mayo Clinic Minnesota , Department of Urology, Mayo Clinic, Rochester, Minnesota 

PubMed